Twin Peaks Wealth Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24	Closed	-$966	–	347
2026 Q1	$966	Buy	+24	New	+$517	﹤0.01%	1911

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Twin Peaks Wealth Advisors's APLS Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 24 shares — an estimated $966 sold.

Twin Peaks Wealth Advisors first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $966 in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 24 Apellis Pharmaceuticals shares in Q2 2026, an estimated $966.
Twin Peaks Wealth Advisors first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Twin Peaks Wealth Advisors's Apellis Pharmaceuticals position peaked at $966 in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.